NO20090574L - Nye proteinkonjugater og fremgangsmater for fremstilling derav - Google Patents
Nye proteinkonjugater og fremgangsmater for fremstilling deravInfo
- Publication number
- NO20090574L NO20090574L NO20090574A NO20090574A NO20090574L NO 20090574 L NO20090574 L NO 20090574L NO 20090574 A NO20090574 A NO 20090574A NO 20090574 A NO20090574 A NO 20090574A NO 20090574 L NO20090574 L NO 20090574L
- Authority
- NO
- Norway
- Prior art keywords
- protein conjugates
- processes
- preparation
- novel protein
- heteroarylamines
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 150000001299 aldehydes Chemical class 0.000 abstract 1
- 150000001448 anilines Chemical class 0.000 abstract 1
- 125000005241 heteroarylamino group Chemical group 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000006268 reductive amination reaction Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Det er beskrevet reduktiv aminering av peptidavledede aldehyder med aniliner eller heteroarylaminer som inneholder en egenskapsmodifiserende gruppe som tilveiebringer nye, hydrolytisk stabile proteinkonjugater som er egnet for terapi.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06116776 | 2006-07-07 | ||
PCT/EP2007/056819 WO2008003750A2 (en) | 2006-07-07 | 2007-07-05 | New protein conjugates and methods for their preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20090574L true NO20090574L (no) | 2009-03-30 |
Family
ID=38701511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20090574A NO20090574L (no) | 2006-07-07 | 2009-02-05 | Nye proteinkonjugater og fremgangsmater for fremstilling derav |
Country Status (15)
Country | Link |
---|---|
US (1) | US9175061B2 (no) |
EP (1) | EP2040757A2 (no) |
JP (1) | JP5252458B2 (no) |
KR (1) | KR20100014215A (no) |
CN (1) | CN101495155A (no) |
AU (1) | AU2007271150A1 (no) |
BR (1) | BRPI0713963A2 (no) |
CA (1) | CA2655188A1 (no) |
IL (1) | IL195839A0 (no) |
MX (1) | MX2008016169A (no) |
NO (1) | NO20090574L (no) |
RU (1) | RU2009103198A (no) |
TW (1) | TW200815477A (no) |
WO (1) | WO2008003750A2 (no) |
ZA (1) | ZA200810821B (no) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
BR9812267B1 (pt) | 1997-07-14 | 2013-11-26 | Hormônio de crescimento recombinante. | |
EP1144613B2 (en) | 1999-01-14 | 2020-05-06 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
JP5977945B2 (ja) | 2008-08-06 | 2016-08-24 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 長期のインビボ有効性を有するコンジュゲートタンパク質 |
ES2542202T3 (es) | 2009-01-22 | 2015-08-03 | Novo Nordisk Health Care Ag | Compuestos de hormonas de crecimiento estables |
JP6086528B2 (ja) * | 2009-08-06 | 2017-03-01 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 長期のインビボ有効性を有する成長ホルモン |
JP5875527B2 (ja) | 2010-01-22 | 2016-03-02 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | in−vivoにおける効力が延長された成長ホルモン |
AU2011208620B2 (en) | 2010-01-22 | 2015-04-16 | Novo Nordisk Health Care Ag | Stable growth hormone compounds |
AU2012210624A1 (en) * | 2011-01-26 | 2013-07-11 | Novo Nordisk A/S | Leptin derivatives |
EP2842546A4 (en) | 2012-04-27 | 2015-12-30 | Univ Tokyo | UNITARY STRUCTURE-TYPE PHARMACEUTICAL COMPOSITION FOR NUCLEIC ACID ADMINISTRATION |
JP6464145B2 (ja) | 2013-04-05 | 2019-02-06 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 成長ホルモン化合物製剤 |
WO2016034534A1 (en) * | 2014-09-01 | 2016-03-10 | Novo Nordisk Health Care Ag | Lysine rich basic pre-sequences |
EP3250636B1 (en) * | 2015-01-27 | 2020-05-06 | Hewlett-Packard Development Company, L.P. | Polymeric amine synergists |
WO2016122455A1 (en) | 2015-01-27 | 2016-08-04 | Hewlett-Packard Development Company, L.P. | Polymeric photoactive agents |
WO2016122454A1 (en) | 2015-01-27 | 2016-08-04 | Hewlett-Packard Development Company, L.P. | Polymeric photo active agents |
EP3677268A4 (en) | 2017-08-31 | 2021-04-21 | The University Of Tokyo | UNIT POLYIONIC COMPLEX FILLED WITH NUCLEIC ACID |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
DK173435B1 (da) | 1983-08-17 | 2000-10-23 | Wellcome Found | Injicerbare præparater samt fremgangsmåder til potentiering af administrering af et hormon til normale hvirveldyr eller til |
GB8610551D0 (en) | 1986-04-30 | 1986-06-04 | Hoffmann La Roche | Polypeptide & protein derivatives |
US6673347B1 (en) | 1986-04-30 | 2004-01-06 | Gryphon Therapeutics | Polypeptide and protein derivatives and process for their preparation |
WO1990003401A1 (en) | 1988-09-30 | 1990-04-05 | Neorx Corporation | Targeting substance-diagnostic/therapeutic agent conjugates having schiff base linkages |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
AU2147192A (en) | 1991-06-28 | 1993-01-25 | Genentech Inc. | Method of stimulating immune response using growth hormone |
NZ246556A (en) | 1991-12-20 | 1996-03-26 | Novo Nordisk As | Pharmaceutical composition of a growth hormone and histidine |
NZ250375A (en) | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
WO1995032003A1 (en) | 1994-05-24 | 1995-11-30 | Amgen Boulder Inc. | Modified insulin-like growth factors |
EP0785276A4 (en) | 1994-09-29 | 2002-01-09 | Ajinomoto Kk | MODIFICATION OF A PEPTIDE AND A PROTEIN |
US5795560A (en) * | 1994-11-01 | 1998-08-18 | Neorx Corporation | Targeting protein-diagnostic/therapeutic agent conjugates having Schiff base linkages |
EP0788375A2 (en) | 1994-11-09 | 1997-08-13 | Robin Ewart Offord | Functionalized polymers for site-specific attachment |
WO1996017929A1 (en) | 1994-12-07 | 1996-06-13 | Novo Nordisk A/S | Polypeptide with reduced allergenicity |
GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
US20020077461A1 (en) | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
JP4410852B2 (ja) | 1996-08-02 | 2010-02-03 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 単一の共有結合n末端水溶性ポリマーを有するポリペプチド |
WO1998013381A1 (fr) | 1996-09-26 | 1998-04-02 | Ajinomoto Co., Inc. | Proteines modifiees physiologiquement actives et compositions medicamenteuses les contenant |
WO1998026747A2 (en) * | 1996-12-17 | 1998-06-25 | Terman David S | Superantigen based methods and compositions for treatment of diseases |
DE60138364D1 (de) | 2000-02-11 | 2009-05-28 | Bayer Healthcare Llc | Gerinnungsfaktor vii oder viia konjugate |
CA2723664A1 (en) | 2000-03-22 | 2001-09-27 | Solulink, Incorporated | Hydrazine-based and carbonyl-based bifunctional crosslinking reagents |
MXPA02012795A (es) | 2000-06-28 | 2004-07-30 | Teva Pharma | Carvedilol. |
JP2004524020A (ja) * | 2001-01-11 | 2004-08-12 | マキシゲン・エイピーエス | 改良された成長ホルモン分子 |
US7049285B2 (en) | 2001-10-31 | 2006-05-23 | Myung-Ok Park | Biocompatible polymers including peptide spacer |
IL162031A0 (en) * | 2001-11-20 | 2005-11-20 | Pharmacia Corp | Chemically-modified human growth hormone conjugates |
WO2004000366A1 (en) | 2002-06-21 | 2003-12-31 | Novo Nordisk Health Care Ag | Pegylated factor vii glycoforms |
AU2003256566A1 (en) | 2002-07-16 | 2004-02-02 | Stuart Bussell | Methods to construct multimeric dna and polymeric protein sequences as direct fusions or with linkers |
JP4430344B2 (ja) | 2002-09-09 | 2010-03-10 | 独立行政法人科学技術振興機構 | 多岐用途型リンカー化合物及びリガンド、並びにそれらの製造方法 |
TWI281864B (en) | 2002-11-20 | 2007-06-01 | Pharmacia Corp | N-terminally monopegylated human growth hormone conjugates and process for their preparation |
KR20060032140A (ko) | 2003-05-30 | 2006-04-14 | 센토코 인코포레이티드 | 트랜스글루타미나아제를 이용한 신규 에리트로포이에틴접합체의 형성 |
WO2005014024A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of a polymer and a protein linked by an oxime linking group |
CN1528797A (zh) | 2003-09-28 | 2004-09-15 | 石油大学(华东) | 含氟碳基团的超高分子量水溶性疏水缔合型聚合物及其制备方法 |
US7524813B2 (en) | 2003-10-10 | 2009-04-28 | Novo Nordisk Health Care Ag | Selectively conjugated peptides and methods of making the same |
EP2263684A1 (en) | 2003-10-10 | 2010-12-22 | Novo Nordisk A/S | IL-21 derivatives |
JP2007508250A (ja) | 2003-10-10 | 2007-04-05 | ノボ ノルディスク アクティーゼルスカブ | 持続性放出製剤における長期作用性分子 |
CN1243022C (zh) | 2003-10-17 | 2006-02-22 | 华东师范大学 | 生物修饰重组人生长激素复合物及其制备方法 |
US20070105770A1 (en) | 2004-01-21 | 2007-05-10 | Novo Nordisk A/S | Transglutaminase mediated conjugation of peptides |
ES2642214T3 (es) | 2004-01-21 | 2017-11-15 | Novo Nordisk Health Care Ag | Conjugación de péptidos mediante transglutaminasa |
NZ548256A (en) | 2004-02-02 | 2010-02-26 | Ambrx Inc | Modified human four helical bundle polypeptides and their uses |
KR20070027621A (ko) | 2004-06-08 | 2007-03-09 | 알자 코포레이션 | 4-성분 축합 반응에 의한 고분자 콘쥬게이트의 제조 |
WO2006042847A2 (en) | 2004-10-18 | 2006-04-27 | Novo Nordisk A/S | Method for the preparation of oxime, thiazolidine, dithiane, dithiolane or hydrazone linked analogues of growth hormone |
EP1805216A2 (en) | 2004-10-18 | 2007-07-11 | Novo Nordisk A/S | Growth hormone conjugates |
BRPI0519170A8 (pt) | 2004-12-22 | 2018-05-08 | Ambrx Inc | formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado |
CN103690936A (zh) | 2004-12-22 | 2014-04-02 | Ambrx公司 | 经修饰的人类生长激素 |
EP1893239A2 (en) | 2005-06-15 | 2008-03-05 | Novo Nordisk Health Care AG | Transglutaminase mediated conjugation of growth hormone |
BRPI0615351A2 (pt) | 2005-08-30 | 2011-05-17 | Novo Nordisk Healthcare Ag | formulações lìquidas de hormÈnio do crescimento peguilado |
AU2006201635A1 (en) | 2005-10-20 | 2007-05-10 | Ludwig Institute For Cancer Research | Novel inhibitors and methods for their preparation |
-
2007
- 2007-07-05 AU AU2007271150A patent/AU2007271150A1/en not_active Abandoned
- 2007-07-05 CA CA 2655188 patent/CA2655188A1/en not_active Abandoned
- 2007-07-05 RU RU2009103198/10A patent/RU2009103198A/ru unknown
- 2007-07-05 JP JP2009518855A patent/JP5252458B2/ja not_active Expired - Fee Related
- 2007-07-05 KR KR20097000749A patent/KR20100014215A/ko not_active Application Discontinuation
- 2007-07-05 CN CNA2007800287048A patent/CN101495155A/zh not_active Withdrawn
- 2007-07-05 BR BRPI0713963-2A patent/BRPI0713963A2/pt not_active IP Right Cessation
- 2007-07-05 WO PCT/EP2007/056819 patent/WO2008003750A2/en active Application Filing
- 2007-07-05 EP EP07802373A patent/EP2040757A2/en not_active Withdrawn
- 2007-07-05 MX MX2008016169A patent/MX2008016169A/es not_active Application Discontinuation
- 2007-07-05 US US12/309,142 patent/US9175061B2/en not_active Expired - Fee Related
- 2007-07-06 TW TW96124584A patent/TW200815477A/zh unknown
-
2008
- 2008-12-10 IL IL195839A patent/IL195839A0/en unknown
- 2008-12-23 ZA ZA200810821A patent/ZA200810821B/xx unknown
-
2009
- 2009-02-05 NO NO20090574A patent/NO20090574L/no unknown
Also Published As
Publication number | Publication date |
---|---|
RU2009103198A (ru) | 2010-08-20 |
US9175061B2 (en) | 2015-11-03 |
KR20100014215A (ko) | 2010-02-10 |
TW200815477A (en) | 2008-04-01 |
MX2008016169A (es) | 2009-01-15 |
CA2655188A1 (en) | 2008-01-10 |
IL195839A0 (en) | 2009-09-01 |
ZA200810821B (en) | 2009-12-30 |
US20110144017A1 (en) | 2011-06-16 |
CN101495155A (zh) | 2009-07-29 |
JP5252458B2 (ja) | 2013-07-31 |
EP2040757A2 (en) | 2009-04-01 |
WO2008003750A2 (en) | 2008-01-10 |
AU2007271150A1 (en) | 2008-01-10 |
BRPI0713963A2 (pt) | 2012-11-27 |
JP2009542769A (ja) | 2009-12-03 |
WO2008003750A3 (en) | 2008-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20090574L (no) | Nye proteinkonjugater og fremgangsmater for fremstilling derav | |
CY1123952T1 (el) | Απομονωση και καθαρισμος αντισωματων αντι-il-13 με την χρηση χρωματογραφιας χημικης συγγενειας πρωτεινης α | |
ECSP088733A (es) | Anticuerpos anti-5t4 y usos de los mismos | |
CY1117963T1 (el) | Αντισωματα που προσδενουν τα il-17a και il-17f | |
NO20092611L (no) | Krystallinsk faststoff Rasagilin base | |
BRPI0508064A (pt) | flavivìrus, composição de vacina e molécula de ácido nucléico | |
CY1117563T1 (el) | Αντισωματα κατα her3 και χρησεις αυτων | |
NO20092052L (no) | Antistoffer og immunkonjugater, og anvendelser derav | |
MX2009012843A (es) | Moleculas de union especificas de virus sincitial respiratorio y medios para producirlas. | |
CR20120371A (es) | Antagonistas de pcsk9 | |
ATE526318T1 (de) | Farnesoid-x-rezeptor-agonisten | |
MX2009008430A (es) | Anticuerpos anti-robo4 y sus usos. | |
BRPI0809366A8 (pt) | polipeptídeos interligados | |
AR061246A1 (es) | Anticuerpos anti- dill4 y metodos que los usan | |
DK2135091T3 (da) | MS-fremgangsmåder til evaluering af glykaner | |
TW200740458A (en) | Vaccination against dengue virus infection | |
WO2010017387A3 (en) | Lapatinib, salts thereof, processes and intermediates for their preparation | |
MX2011010012A (es) | NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS. | |
CU20120021A7 (es) | Derivados amido espirocíclicos | |
WO2011019932A3 (en) | Compositions and methods for the therapy and diagnosis of influenza | |
BRPI0815378A2 (pt) | as160 como proteína do tipo as160, sistemas de teste, métodos e usos envolvendo a mesma para identificação de terapêutica para diabetes tipo 2 | |
SV2005002015A (es) | Procesos para la preparacion de haluros de aril- y heteroaril-alquilsulfonilo - ref. wyth0008-504 (am101302) | |
BR112012013325A2 (pt) | Composição farmacêutica e uso | |
BRPI0921371A2 (pt) | Células-tronco para uso terapêutico que são derivados de monócito humano, e método para induzir as mesmas. | |
BR112012012783A2 (pt) | produto de reação não reticulado de um composto epóxi e oxetano e um silicone amino |